Novo Nordisk invests €432m in Ireland for Wegovy pill production

• By Alex Cooke

It will “support the upgrade and retrofit of the existing facility” and “enhance Novo Nordisk’s capacity to manufacture oral GLP-1s” (Shutterstock) Share current article via EmailShare current article via FacebookShare current article via PinterestShare current article via TwitterShare current article via LinkedIn